Get the jury some takeout... After a whopping 50 hours of deliberations, jurors found Theranos founder Elizabeth Holmes guilty on 4 of 11 charges in her criminal trial. The 37-year-old was convicted of three fraud counts against investors in her disgraced blood-testing startup, and one count of conspiracy to commit fraud.
Bad blood money... Theranos claimed that with just a few finger pricks of blood its tests could detect health conditions from cancer to high cholesterol. Holmes raised $900M+ from investors, growing the company to a $9B valuation and becoming the youngest female self-made billionaire on paper. Holmes was convicted for lying to investors about the accuracy of Theranos' machines. And still…
Industry investors are mostly unfazed... Theranos doesn’t seem to have dramatically changed how investors select companies to fund, or how openly startups share information. Notably, Theranos’ funding wasn’t typical of the traditional Silicon Valley model — it was largely backed by prominent individuals (like Walmart's Walton family and Rupert Murdoch). Also notable: Theranos’ board was light on medical experts, while including distinguished former national-security leaders (James Mattis, Henry Kissinger). Still, the Theranos saga shows the importance of rigor and transparency when it comes to due diligence.